Medtronic MDT Business Segments
| Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | ||
|---|---|---|---|---|---|---|
| Net Sales by Business | ||||||
| Cardiovascular | $3.8B+13.8% | $3.46B+13.8% | $3.44B+10.8% | $3.29B+9.2% | $3.34B+6.6% | |
| Diabetes | $838M+15.1% | $796M+14.7% | $757M+10.3% | $721M+11.4% | $728M+10.5% | |
| Medical Surgical | $2.39B+8.0% | $2.17B+4.9% | $2.17B+2.0% | $2.08B+4.4% | $2.21B+0.6% | |
| Neuroscience | $2.75B+5.0% | $2.56B+4.1% | $2.56B+4.5% | $2.42B+4.3% | $2.62B+2.9% | |
| Other Operating Segments | $33.75M-1.5% | $33.75M-1.5% | $33.75M-1.5% | $33.75M-1.5% | $34.25M-38.0% | |
| Reportable segment operating profit by Business | ||||||
| Cardiovascular | $1.07B+11.8% | $899M+8.6% | $877M+12.3% | $828M+6.2% | $955M— | |
| Medical Surgical | $605M+5.2% | $499M-2.5% | $531M+1.1% | $494M+7.6% | $575M— | |
| Neuroscience | $879M+2.4% | $737M-3.3% | $740M+2.1% | $705M+2.6% | $858M— | |
| Other segment items by Business | ||||||
| Cardiovascular | -$1M+92.9% | -$14M0.0% | -$17M-143% | -$15M-150% | -$14M-100% | |
| Medical Surgical | $5M+25.0% | $6M+50.0% | $2M-60.0% | $1M-80.0% | $4M+77.8% | |
| Neuroscience | $13M+8.3% | $12M0.0% | $9M+325% | $2M-81.8% | $12M+60.0% | |
| Cost of products sold, excluding amortization of intangible assets by Business | ||||||
| Cardiovascular | $1.27B+13.0% | $1.16B+20.2% | $1.13B+8.0% | $1.13B+13.4% | $1.12B+15.5% | |
| Medical Surgical | $964M+10.8% | $867M+10.0% | $831M+1.5% | $814M+4.6% | $870M+9.8% | |
| Neuroscience | $843M+7.0% | $815M+14.5% | $772M+4.5% | $721M+9.7% | $788M+14.2% | |
| Selling, general, and administrative expense by Business | ||||||
| Cardiovascular | $1.19B+17.4% | $1.13B+11.8% | $1.14B+11.9% | $1.06B+8.4% | $1.01B+3.8% | |
| Medical Surgical | $650M+9.6% | $628M+3.8% | $627M+3.0% | $605M+2.4% | $593M-1.2% | |
| Neuroscience | $875M+7.6% | $841M+2.6% | $874M+4.8% | $831M+2.8% | $813M+2.6% | |
| Currency translation and other by Business | ||||||
| Cardiovascular | $10M-88.6% | $9M+121% | —— | $28M+155% | $88M+540% | |
| Medical Surgical | $110M-84.8% | $54M+115% | —— | $203M+164% | $725M+455% | |
| Neuroscience | $20M-81.1% | $19M+133% | —— | $38M+280% | $106M+453% | |
| Other Operating Segments | $0-100% | $0-100% | $0-100% | $0-100% | $250K— | |
| Depreciation by Business | ||||||
| Cardiovascular | $67M+15.5% | $66M+17.9% | $56M0.0% | $64M+16.4% | $58M+16.6% | |
| Medical Surgical | $56M+5.7% | $62M+21.6% | $53M+3.9% | $54M+10.2% | $53M+9.3% | |
| Neuroscience | $85M+18.1% | $80M+9.6% | $79M+11.3% | $77M+18.5% | $72M+14.3% | |
| Research and development expense by Business | ||||||
| Cardiovascular | $273M+5.4% | $284M+14.5% | $299M+16.8% | $280M+8.9% | $259M+4.5% | |
| Medical Surgical | $163M-3.6% | $174M+6.1% | $181M+5.8% | $169M+4.3% | $169M+4.6% | |
| Neuroscience | $139M-6.7% | $153M+0.7% | $167M+5.7% | $157M+2.6% | $149M-4.5% | |
| Net Sales by Geography | ||||||
| Ireland | $39M+30.0% | $36M+28.6% | $35M+20.7% | $33M+10.0% | $30M+11.1% | |
| Rest of world | $4.9B+12.6% | $4.49B+11.4% | $4.41B+8.4% | $4.32B+13.6% | $4.35B+3.1% | |
| United States | $4.87B+7.1% | $4.49B+6.0% | $4.52B+4.9% | $4.22B+3.5% | $4.55B+4.7% | |
| Property, plant, and equipment, net by Geography | ||||||
| Ireland | $338M+16.2% | —— | —— | —— | $291M+15.5% | |
| Rest of world | $1.62B+14.8% | —— | —— | —— | $1.41B+10.0% | |
| United States | $5.46B+6.3% | —— | —— | —— | $5.13B+11.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Medtronic break its business down?
- Medtronic (MDT) reports net sales by business across 6 parts — Cardiovascular, Diabetes, Medical Surgical, Neuroscience and Other operating segment. Each is extracted from the segment footnotes and tracked over time.
- Where does Medtronic's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Medtronic's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
